Using RNA Diagnostics to Predict Patient Response to Immunotherapies

Cofactor Genomics believes RNA provides a better means than DNA and other biomarkers to diagnose disease, monitor health, and enhance treatment decisions. The company’s Predictive Immune Modeling provides insight into a cancer patient’s immune response at the tumor to determine whether an individual is likely to response to an immunotherapy. We spoke to Jarret Glasscock, founder and CEO of Cofactor Genomics, about its RNA diagnostics, the case for the use of multidimensional biomarkers, and the challenges it faces with physician adoption and reimbursement.